Related Experiment Video

Updated: May 10, 2026

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

Investigational cytokine-targeted therapies for ulcerative colitis

Giovanni Monteleone1, Francesco Pallone, Flavio Caprioli

  • 1University of Rome "Tor Vergata", Department of Systems Medicine, Via Montpellier 1, Rome, 00133, Italy. Gi.Monteleone@Med.uniroma2.it

Expert Opinion on Investigational Drugs
|June 28, 2013
PubMed
Abstract

Insights

Novel cytokine-based therapies show promise for ulcerative colitis (UC) treatment, offering new options for patients unresponsive to traditional medications. Careful consideration of patient heterogeneity and potential side effects is crucial for successful therapeutic strategies.

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Ulcerative colitis (UC) affects a significant patient population, with up to one-third showing resistance to standard treatments like mesalamine, steroids, and thiopurines.
  • The pathophysiology of UC involves an imbalance in inflammatory and counter-regulatory signals, primarily mediated by cytokines.
  • This understanding has spurred the development of novel therapeutic compounds targeting these cytokine pathways.

Purpose of the Study:

  • To review recent advancements in cytokine-based therapies for ulcerative colitis (UC).
  • To evaluate the efficacy of compounds inhibiting inflammatory cytokines or enhancing counter-regulatory cytokines in UC patients and murine models.
  • To discuss the potential and challenges of these novel treatments in clinical practice.

Main Methods:

  • A comprehensive literature search was conducted using PubMed with keywords: 'ulcerative colitis', 'therapy', 'treatment', and 'cytokine'.
  • Information on ongoing clinical trials was gathered.
  • Pharmaceutical company websites were consulted to identify relevant compounds.

Main Results:

  • Investigational cytokine-based therapies have demonstrated promising results in reducing clinical activity in both UC patients and experimental colitis models.
  • These novel compounds target key inflammatory and counter-regulatory cytokine pathways implicated in UC pathogenesis.

Conclusions:

  • Cytokine-based therapies represent a promising frontier for ulcerative colitis treatment, particularly for patients with refractory disease.
  • Potential challenges include the clinical and immunological heterogeneity of UC patients, therapy-related side effects, and the complex biological functions of cytokines.
  • Optimizing therapeutic strategies requires careful consideration of these factors to ensure effective and safe treatment outcomes.

More Related Videos

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...